贝伐珠单抗联合TP方案同步放疗治疗复发性宫颈癌的疗效观察

Clinical Observation of Bevacizumab Combined with TP Regimen and Concurrent Radiotherapy for Recurrent Cervical Cancer

目的探讨贝伐珠单抗联合TP方案同步放疗治疗复发性宫颈癌的疗效。方法选取200例复发性宫颈癌患者为研究对象,按照治疗方法进行分组。对照组患者行TP方案同步放疗治疗,观察组患者采用贝伐珠单抗联合TP方案同步放疗治疗,比较2组治疗效果。结果观察组治疗有效率为82.22%(74/90),高于对照组的64.55%(71/110),差异具有统计学意义(P<0.05)。治疗后2组患者血清鳞状细胞癌相关抗原(SCC-Ag)、癌胚抗原(CEA)及细胞角蛋白19片段抗原21-1(CYFRA21-1)水平均较治疗前下降(P<0.05),且观察组均低于对照组(P<0.05)。治疗期间,2组患者3~4级不良反应发生率比较,差异无统计学意义(P>0.05)。结论在TP方案同步放疗的基础上联合贝伐珠单抗治疗复发性宫颈癌能够提升疗效,降低血清肿瘤标志物水平,且安全性良好。

Objective To investigate the efficacy of Bevacizumab combined with TP regimen and concurrent radiotherapy in the treatment of recurrent cervical cancer.Methods A total of 200 patients with recurrent cervical cancer were selected as the study objects and grouped according to the treatment method.The patients in the control group were treated with TP regimen and concurrent radiotherapy,and the patients in the observation group were treated with Bevacizumab combined with TP regimen and concurrent radiotherapy.The therapeutic effects of the two groups were compared.Results The effective rate of treatment in the observation group was 82.22%(74/90),which was higher than 64.55%(71/110)in the control group(P<0.05);after treatment,the levels of serum squamous cell carcinoma associated antigen(SCC-Ag),carcinoembryonic antigen(CEA)and cell Keratin 19 fragment antigen 21-1(CYFRA21-1)in the two groups were decreased compared with those before treatment(P<0.05),and the levels in the observation group were lower than those in the control group(P<0.05);during the treatment period,there was no statistically great difference in the incidence of grade 3-4 side reactions between the two groups(P>0.05).Conclusion Bevacizumab in the treatment of recurrent cervical cancer can improve the efficacy,reduce the level of serum tumor markers,and has good safety in patients with recurrent cervical cancer undergoing TP regimen and simultaneous radiotherapy.